Table 1.
Demographic characteristics and participant disposition in two trials conducted between 2015 and 2018 that assessed the pharmacokinetics and pharmacodynamics of MPA when Depo-Provera is administered subcutaneously rather than by the labeled intramuscular route [10,11]1
| Study 702179(n = 41) | Study 834119(n = 60) | Total(n = 101) | |
|---|---|---|---|
| Age (years) | |||
| Median (Range) | 34 (25–39) | 33 (22–40) | 34 (22–40) |
| > 35 | 16 (39.0%) | 24 (40.0%) | 40 (39.6%) |
| Race | |||
| White | 3 (7.3%) | 33 (55.0%) | 36 (35.6%) |
| Biracial2 or black | 38 (92.7%) | 27 (45.0%) | 65 (64.4%) |
| BMI (kg/m2) | |||
| Median (Range) | 26.6 (18.1–32.8) | 26.7 (19.0–33.9) | 26.6 (18.1–33.9) |
| < 25 | 13 (31.7%) | 21 (35.0%) | 34 (33.7%) |
| 25 to 30 | 18 (43.9%) | 25 (41.7%) | 43 (42.6%) |
| > 30 | 10 (24.4%) | 14 (23.3%) | 24 (23.8%) |
| Study disposition | |||
| Completed follow-up | 41 (100%) | 54 (90.0%) | 95 (94.1%) |
| Ovulated | 35 (85.4%)3 | 24 (40.0%) | 59 (58.4%) |
1
Study 702179 [10] was conducted in the Dominican Republic and the USA. Study 834119 [11] was conducted in Brazil, Chile, and the Dominican Republic. Data presented are n (%) unless otherwise noted.
2
Greater than 90% of participants identifying as biracial were of African and European descent.
3
Includes 16 ovulations detected after the primary 12-month follow-up period.